Literature DB >> 11153449

A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

E H Cox1, C Veyrat-Follet, S L Beal, E Fuseau, S Kenkare, L B Sheiner.   

Abstract

This paper presents and illustrates methodology for specifying, estimating, and evaluating a predictive model for repeated measures time-to-event responses. The illustrative example specifies a model of the antiemetic effect vs. concentration relationship for the 5-HT3 antagonist ondansetron in the human ipecac model for emesis. A key part of this model is a time-dependent log hazard function for emesis that is increased by ipecac administration and decreased by ondansetron concentration. The model is fit using an approximate maximum likelihood method. The data consist of the time free of emeses and, for those individuals with emetic episodes, the time(s) of the episode(s). Model evaluation is accomplished using residual plots adapted to time-to-event data and a "posterior predictive check" wherein observed data statistics are compared to those obtained from data simulated from the fitted model. The ondansetron concentration required to obtain a 50% reduction in the hazard of emesis is estimated to be 1.4 +/- 0.2 ng/ml, and the rate constant for elimination of ipecac-induced hazard is 1.5 +/- 0.2 hr-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11153449     DOI: 10.1023/a:1020930626404

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

Review 1.  Simulation of clinical trials.

Authors:  N H Holford; H C Kimko; J P Monteleone; C C Peck
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

3.  A general framework for random effects survival analysis in the Cox proportional hazards setting.

Authors:  D J Sargent
Journal:  Biometrics       Date:  1998-12       Impact factor: 2.571

4.  Efficacy measures: surrogates or clinical outcomes?

Authors:  J W Blue; W A Colburn
Journal:  J Clin Pharmacol       Date:  1996-09       Impact factor: 3.126

Review 5.  Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview.

Authors:  J Dingemanse; M Danhof; D D Breimer
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

6.  A sensitive radioimmunoassay, combined with solid-phase extraction, for the sub-nanogram per ml determination of ondansetron in human plasma.

Authors:  S A Wring; R M Rooney; C P Goddard; I Waterhouse; W N Jenner
Journal:  J Pharm Biomed Anal       Date:  1994-03       Impact factor: 3.935

7.  Population pharmacodynamic model for ketorolac analgesia.

Authors:  J W Mandema; D R Stanski
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

8.  Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.

Authors:  N Minton; R Swift; C Lawlor; T Mant; J Henry
Journal:  Clin Pharmacol Ther       Date:  1993-07       Impact factor: 6.875

9.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

10.  Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly.

Authors:  P V Colthup; C C Felgate; J L Palmer; N L Scully
Journal:  J Pharm Sci       Date:  1991-09       Impact factor: 3.534

View more
  27 in total

1.  Application of a hazard-based visual predictive check to evaluate parametric hazard models.

Authors:  Yeamin Huh; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-13       Impact factor: 2.745

Review 2.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

3.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

Review 4.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Performance of three estimation methods in repeated time-to-event modeling.

Authors:  Kristin E Karlsson; Elodie L Plan; Mats O Karlsson
Journal:  AAPS J       Date:  2011-01-13       Impact factor: 4.009

6.  Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools.

Authors:  Sebastiaan C Goulooze; Elke H J Krekels; Thomas Hankemeier; Catherijne A J Knibbe
Journal:  AAPS J       Date:  2018-12-18       Impact factor: 4.009

Review 7.  Pharmacodynamic models for discrete data.

Authors:  Ines Paule; Pascal Girard; Gilles Freyer; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

8.  Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

9.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

10.  Evaluation of estimation methods and power of tests of discrete covariates in repeated time-to-event parametric models: application to Gaucher patients treated by imiglucerase.

Authors:  Marie Vigan; Jérôme Stirnemann; France Mentré
Journal:  AAPS J       Date:  2014-02-26       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.